Disclosure: M.Y., X.S., J.C., J.D., L.Z., Z.D., J.L., T.C., J.P.W., Y.C. and Q.L. are presently employees of Crown Bioscience, Inc. Y.C. is also a shareholder of Crown bioscience, Inc.
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients†
Article first published online: 3 OCT 2012
Copyright © 2012 UICC
International Journal of Cancer
Volume 132, Issue 2, pages E74–E84, 15 January 2013
How to Cite
Yang, M., Shan, B., Li, Q., Song, X., Cai, J., Deng, J., Zhang, L., Du, Z., Lu, J., Chen, T., Wery, J.-P., Chen, Y. and Li, Q. (2013), Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients. Int. J. Cancer, 132: E74–E84. doi: 10.1002/ijc.27813
- Issue published online: 20 NOV 2012
- Article first published online: 3 OCT 2012
- Accepted manuscript online: 5 SEP 2012 04:11AM EST
- Manuscript Accepted: 21 AUG 2012
- Manuscript Received: 13 JUL 2012
Additional Supporting Information may be found in the online version of this article.
|IJC_27813_sm_SuppFig1.tif||4076K||Supporting Information Figure 1|
|IJC_27813_sm_SuppFig2A.tif||1164K||Supporting Information Figure 2A|
|IJC_27813_sm_SuppFig2B.tif||1995K||Supporting Information Figure 2B|
|IJC_27813_sm_SuppFig2C.tif||2111K||Supporting Information Figure 2C|
|IJC_27813_sm_SuppFig2D.tif||2003K||Supporting Information Figure 2D|
|IJC_27813_sm_SuppFig2E.tif||2064K||Supporting Information Figure 2E|
|IJC_27813_sm_SuppTab1.pdf||81K||Supporting Information Table 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.